Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 392007 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
Hard CopyAdd to Basket
ElectronicAdd to Basket



Commercial Insight: Cardiovascular Market Overview - Raft of Patent Expires Threaten Blockbusters
Datamonitor, Oct 2007, Pages: 262


  Description  
  Table of Contents  
  Companies Mentioned  
    
    
   
 Enquire before Buying  
 Send to a Friend  

Introduction

The cardiovascular market is exptected to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of products will have lost IP protection, accounting for 30% of cardiovascular sales and 65% of SU sold in 2016.

Scope

- Comprehensive analysis of the cardiovascular market by disease area in each of the seven major markets
- An assessment of trends within the cardiovascular market between 2003 and 2006.
- Intellectual Property risk assessment for Top 10 brands in each market.
- Forecast models for key brands, active agents and pipeline products up to 2016.

Highlights

The cardiovascular market in the seven major markets is a mature market with negligible sales growth between 2006 and 2016. Growth of SU sold in the cardiovascular market is expected to increase by 3%, driven by population growth, leaving an effective cardiovascular sales growth of -3%. Use of generics will increase as key products lose patent protection and healthcare providers push for greater cost containment. Patent expiries during the pivotal 2010-13 window expose $30.9 billion worth of branded drugs to generic competition. Cardiovascular pipeline products are unlikely to make a significant impact on the market with only 16% ($11.9 billion) of 2016 sales generated from the current pipeline. A number of blockbuster products are likely to be launched but the sales are likely to be greatly reduced from the levels seen in 2006.

Reasons to Purchase

- Understand market specific drivers and predict the future potential of key cardiovascular brands
- Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics
- Consider, assess and react to opportunities and risks influencing the leading cardiovascular brands




Customers who bought this item also bought

China Top 50 City Commercial Banks Report, 2006

Thailand Commercial Vehicle Markets

Industrial & Commercial Bank of China - Company Profile, Financials and Condensed Data

IntelliNews Romanian Commercial Real Estate Report

U.S. Commercial Casino Industry�2006�

Electrometallurgical Ferroalloy Product Manufacturing Industry in the U.S. and its Foreign Trade

Commercial Vehicles Report November 2006

Malaysian Commercial Vehicle Telematics Markets



Top of page


   All rights reserved. � Copyright 2008 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds